National Pension Service Purchases 6,199 Shares of Zimmer Biomet Holdings, Inc. $ZBH

National Pension Service grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.2% during the second quarter, Holdings Channel reports. The institutional investor owned 199,437 shares of the medical equipment provider’s stock after purchasing an additional 6,199 shares during the quarter. National Pension Service’s holdings in Zimmer Biomet were worth $17,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Main Management ETF Advisors LLC increased its holdings in Zimmer Biomet by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after acquiring an additional 112 shares during the last quarter. Citizens National Bank Trust Department boosted its position in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 141 shares during the period. TD Private Client Wealth LLC increased its stake in shares of Zimmer Biomet by 15.3% in the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 153 shares in the last quarter. Leonteq Securities AG increased its stake in shares of Zimmer Biomet by 5.3% in the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after purchasing an additional 153 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its position in shares of Zimmer Biomet by 5.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,133 shares of the medical equipment provider’s stock valued at $282,000 after purchasing an additional 162 shares during the period. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZBH shares. Sanford C. Bernstein raised their price objective on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Truist Financial increased their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Citigroup cut their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Finally, Canaccord Genuity Group boosted their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $93.47 on Friday. The company has a 50 day moving average of $95.54 and a 200 day moving average of $91.52. The stock has a market cap of $17.83 billion, a P/E ratio of 22.74, a P/E/G ratio of 1.76 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $106.88. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the prior year, the company posted $2.07 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Transactions at Zimmer Biomet

In related news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.